Phaseline

Targets › AGTR1

AGTR1 (Type-1 angiotensin II receptor): drug programs, companies and trials

18 programs from 18 companies in 169 trials: 57 Phase 2, 53 Phase 4, 33 Phase 1, 26 Phase 3; Cardiovascular, Oncology, Neurology; next expected readout Nov 2026.

Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney. The activated receptor in turn couples to G-alpha proteins G(q) (GNAQ, GNA11, GNA14 or GNA15) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C..; FUNCTION:…. (UniProt, P30556)

Open in Phaseline: the race on AGTR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
Travere TherapeuticsSparsentan
Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist
EDNRA, AGTR1Phase 4Proteinuria; Immunoglobulin A Nephropathy; Focal Segmental Glomerulosclerosis; ANCA Associated VasculitisMar 2027
National Heart Centre SingaporeRenin-angiotensin-aldosterone system inhibitors (ACE inhibitors, Angiotensin II
ACE inhibition and angiotensin II receptor antagonism
ACE, AGTR1Phase 4Diabetes MellitusJun 2034
Yan LiAlisartan
Angiotensin II receptor antagonist
AGTR1Phase 4Hypertension–
Shenzhen Salubris PharmaceuticalsLosartan
Type-1 angiotensin II receptor antagonist
AGTR1Phase 4Healthy Participants; Atrial Fibrillation; Diabetes Mellitus, Type 2; Heart Valve Diseases …–
YuhanTelmisartan
Type-1 angiotensin II receptor antagonist
AGTR1Phase 4Essential Hypertension–
Sherief Abd-ElsalamAngiotensin receptor blockers (ARBs)
Angiotensin II type 1 receptor antagonist
AGTR1Phase 3Rheumatoid ArthritisDec 2026
THPharmTelmisartan (THP-00102)
Type-1 angiotensin II receptor antagonist
AGTR1Phase 3Type 2 Diabetes; Parkinsons Disease (PD); Ovarian Cancer; Prostate CancerDec 2026
Chong Kun Dang PharmaceuticalValsartan
Type-1 angiotensin II receptor antagonist
AGTR1Phase 3Essential Hypertension; Stage D Heart Failure; PreDiabetes; Coronary Artery Disease …Dec 2026
Chia Tai Tianqing Pharmaceutical GroupAngiotensin Ii
Type-1 angiotensin II receptor agonist
AGTR1Phase 3Vasodilatory Shock; Vasodilatory Hypotension During or After Cardiac Surgery; Cirrhosis, Liver; Septic Shock …Jun 2027
Assistance Publique - Hôpitaux de ParisIRBESARTAN
Type-1 angiotensin II receptor antagonist
AGTR1Phase 3Acute Kidney Injury–
OHSU Knight Cancer InstituteLosartan Potassium
Type-1 angiotensin II receptor antagonist
AGTR1Phase 2Pancreatic AdenocarcinomaJan 2027
HB BioTechHB-1
Angiotensin II receptor antagonist (telmisartan) and calcium channel blocker (verapamil)
AGTR1, Ion channelsPhase 2PTSDSep 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOlmesartan
Type-1 angiotensin II receptor antagonist
AGTR1Phase 2HR+ / HER2- Advanced Breast CancerJun 2028
Shin Poong PharmaceuticalCandesartan (SPC1001)
Type-1 angiotensin II receptor antagonist
AGTR1Phase 2Hypertension, Essential; Cardiomyopathy, Dilated; Liver Fibroses–
Steadman Philippon Research InstituteLosartan potassium
Type-1 angiotensin II receptor antagonist
AGTR1Phase 1Knee Arthroplasty, TotalJun 2027
David K CarrollArginine hydrochloride
L-arginine nitric oxide donor; stimulates pancreatic insulin secretion via nitric oxide-me
AGTR1Phase 1Diabetes (DM)Oct 2027

Conditions

Obstructive Sleep Apnea (4) Type 2 Diabetes (3) Prostate Cancer (3) Essential Hypertension (3) Hypertension (3) Nicotine Dependence (3) PreDiabetes (2) Breast Cancer (2) Heart Failure (2) Heart Failure With Reduced Ejection Fraction (2) Diabetes Mellitus (2) Proteinuria (2)

Modalities

small molecule (15), mixed (2)

Companies

THPharm (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) HB BioTech (1) Chong Kun Dang Pharmaceutical (1) Yuhan (1) Shenzhen Salubris Pharmaceuticals (1) Travere Therapeutics (1) Yan Li (1) Steadman Philippon Research Institute (1) Sherief Abd-Elsalam (1) David K Carroll (1) University of California, San Francisco (1) Brigham and Women's Hospital (1) National Heart Centre Singapore (1) Assistance Publique - Hôpitaux de Paris (1) Shin Poong Pharmaceutical (1) Chia Tai Tianqing Pharmaceutical Group (1) OHSU Knight Cancer Institute (1)

Related targets

HTR2A (2) OPRM1 (2) Ion channels (1) EDNRA (1) ADRB2 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.